| Literature DB >> 33443667 |
Corrado Cabona1, Pilar M Ferraro2, Giuseppe Meo3, Luca Roccatagliata2, Angelo Schenone3, Matilde Inglese3, Flavio Villani4, Claudia Caponnetto3.
Abstract
INTRODUCTION: Factors influencing self-perceived health status over Corona Virus Disease 2019 (COVID-19) emergency in vulnerable populations, such as patients with chronic neurological diseases, are still unknown. In this work, we aimed at testing whether clinical care changes imposed by the quarantine, together with certain demographic and disease-specific features, might have determined a self-perceived worsening of health status in patients with amyotrophic lateral sclerosis (ALS).Entities:
Keywords: Amyotrophic lateral sclerosis; Anxiety; Corona virus disease 2019; Depression; Motor worsening
Mesh:
Year: 2021 PMID: 33443667 PMCID: PMC7807220 DOI: 10.1007/s10072-020-04997-z
Source DB: PubMed Journal: Neurol Sci ISSN: 1590-1874 Impact factor: 3.830
Demographic and disease-specific features of ALS patients
| Number | 57 | 14 | – |
| Age [years] | 66.54 (11.54) | 65.92 (10.54) | 0.82 |
| Gender [females] | 23 (40.36%) | 7 (50.00%) | 0.72 |
| Site of onset [bulbar] | 10 (17.54%) | 3 (21.42%) | 1.00 |
| Clinical phenotype [classic/bulbar/flail arm/flail leg/UMN/pseudopolyneuritic] | 30 (52.63%)/7 (12.28%)/1 (1.75%) /5 (8.78%)/9 (15.78%)/5 (8.78%) | 7 (50.00%)/2 (14.28%)/0 (0.00%)/1 (7.14%)/3 (21.42%)/1 (7.14%) | 0.98 |
| Disease duration [months] | 53.31 (35.08) | 50.57 (41.03) | 0.10 |
| ALSFRS-r [0–48] | 30.59 (11.36) | 37.67 (6.36) | 0.09 |
| Clinical progression rate [ALSFRS-r rate of decline per month] | 0.41 (0.32) | 0.44 (0.47) | 0.60 |
| Under treatment with NIV | 19 (33.33%) | 4 (28.57%) | 0.94 |
Values are means (standard deviations) or frequencies (percentages). P values refer to Mann-Whitney U-Test or Chi-Square test
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-r, ALS functional rating scale-revised; NIV, noninvasive ventilation; UMN, upper motor neuron
Self-perceived mental and physical health status and clinical care variables
| Self-perceived anxiety symptoms | 20 (35.08%) |
|---|---|
| Severity of self-perceived anxiety symptoms [ | 1.65 (0.74) |
| Self-perceived depressive symptoms | 21 (36.84%) |
| Severity of self-perceived depressive symptoms [ | 1.61 (0.66) |
| Self-perceived clinical worsening | 20 (35.08%) |
| Selective motility decline | 10 (50.00%) |
| Motility and respiratory symptoms | 6 (30.00%) |
| Selective respiratory worsening | 1 (5.00%) |
| Selective increase of pain symptoms | 1 (5.00%) |
| Motility and pain symptoms | 1 (5.00%) |
| Mixed symptoms | 1 (5.00%) |
| Difficulties in retrieving medicines | 2 (3.50%) |
| Exams and/or visits cancelation | 36 (63.15%) |
| Following a rehabilitation therapy | 43 (75.44%) |
| Rehabilitation therapy suspension | 34 (79.06%) |
Values are means (standard deviations) or frequencies (percentages)
Ordinal and logistic regression analyses results
| Variable | OR (CI 95%) | |
|---|---|---|
| Age | 1.00 (0.98, 1.02) | 0.46 |
| Gender [female] | 1.62 (1.02, 2.59) | 0.04 |
| Site of onset [bulbar] | 0.80 (0.42, 1.49) | 0.49 |
| Disease duration | 0.99 (0.99, 1.00) | 0.48 |
| ALSFRS-r | 0.97 (0.95, 0.99) | 0.02 |
| Clinical progression rate | 3.26 (1.69, 6.30) | < 0.001 |
| NIV [yes] | 1.18 (0.71, 1.96) | 0.51 |
| Exams and/or visits cancelation [yes] | 1.59 (0.98, 2.56) | 0.06 |
| Rehabilitation suspension [yes] | 1.70 (1.07, 2.70) | 0.02 |
| Variable | OR (CI 95%) | |
| Age | 1.00 (0.98, 1.02) | 0.48 |
| Gender [female] | 1.46 (0.92, 2.32) | 0.10 |
| Site of onset [bulbar] | 0.88 (0.48, 1.63) | 0.70 |
| Disease duration | 1.00 (0.99, 1.00) | 0.69 |
| ALSFRS-r | 0.98 (0.96, 1.00) | 0.19 |
| Clinical progression rate | 1.99 (1.00, 3.96) | 0.05 |
| NIV [yes] | 1.12 (0.68, 1.84) | 0.64 |
| Exams and/or visits cancelation [yes] | 1.51 (0.95, 2.41) | 0.08 |
| Rehabilitation suspension [yes] | 1.05 (0.65, 1.68) | 0.82 |
| Variable | OR (CI 95%) | |
| Age | 1.01 (0.96, 1.06) | 0.64 |
| Gender [female] | 1.84 (0.61, 5.67) | 0.27 |
| Site of onset [bulbar] | 0.75 (0.14, 3.12) | 0.71 |
| Disease duration | 0.97 (0.95, 0.99) | 0.05 |
| ALSFRS-r | 1.00 (0.95, 1.05) | 0.94 |
| Clinical progression rate | 4.49 (0.83, 32.62) | 0.09 |
| NIV [yes] | 1.71 (0.53, 5.48) | 0.35 |
| Exams and/or visits cancelation [yes] | 9.49 (2.30, 65.31) | 0.005 |
| Rehabilitation suspension [yes] | 2.84 (0.89, 10.22) | 0.08 |
Abbreviations: OR, odds ratio; CI, confidence interval